eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc. (Nasdaq: EFTR) became a publicly traded company through its August 2021 business combination with Locust Walk Acquisition Corp., a blank-check vehicle sponsored by Locust Walk Partners that completed its IPO in 2021. The 8-K filed August 24, 2021, accession number 0001193125-21-255206, reported the closing of that de-SPAC transaction. eFFECTOR is a clinical-stage biopharmaceutical company operating in the oncology sector, with its pipeline centered on translation regulation — specifically targeting the eIF4F complex — as a mechanism to disrupt cancer cell survival. The combined company trades on Nasdaq under the ticker EFTR. Sign up at SpacDesk for full filing history, deal metrics, and real-time data on eFFECTOR and hundreds of other SPAC transactions.